Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study-Reference-Cited by-同舟云学术

Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study

Published:2018-02 Issue:2 Volume:5 Page:e82-e94
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Dartigeas Caroline,Van Den Neste Eric,Léger Julie,Maisonneuve Hervé,Berthou Christian,Dilhuydy Marie-Sarah,De Guibert Sophie,Leprêtre Stéphane,Béné Marie C,Nguyen-Khac Florence,Letestu Rémi,Cymbalista Florence,Rodon Philippe,Aurran-Schleinitz Thérèse,Vilque Jean-Pierre,Tournilhac Olivier,Mahé Béatrice,Laribi Kamel,Michallet Anne-Sophie,Delmer Alain,Feugier Pierre,Lévy Vincent,Delépine Roselyne,Colombat Philippe,Leblond Véronique

Publisher

Elsevier BV

Subject

Hematology

Reference30 articles.

1. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia;Rai;N Engl J Med,2000

2. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia;Eichhorst;Blood,2006

3. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia;Keating;J Clin Oncol,2005

4. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011;Byrd;Blood,2005

5. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial;Eichhorst;Lancet Oncol,2016

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global burden, risk factor analysis, and prediction study of leukaemia from 1990 to 2030;Journal of Global Health;2024-08-23

2. Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma;Leukemia & Lymphoma;2024-06-10

3. Two‐stage randomized clinical trials with a right‐censored endpoint: Comparison of frequentist and Bayesian adaptive designs;Statistics in Medicine;2024-06-06

4. Improving the external validity of randomized clinical trials: The interesting place of weighting survey methods;2024-04-29

5. Prognostic impact of genetic abnormalities in 536 first‐line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV‐mutated subgroups (a FILO study);British Journal of Haematology;2024-04-23